Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy, safety and feasibility of four weeks of sofosbuvir
plus glecaprevir-pibrentasvir, followed by immediate retreatment of virological relapse with
glecepravir-pibrentasvir for 12 weeks, in treatment-naïve participants with chronic HCV
infection and early liver disease (F0-F2).